Annual Meeting 2014: Results of CHAMPION-1 investigating weekly carfilzomib in combination with dex for R/R MM

James R. Berenson, MD
Institute for Myeloma & Bone Cancer Research
West Hollywood, California, USA

Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma

Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US for the treatment of relapsed and refractory multiple myeloma (MM). This multicenter, single-arm phase 1/2 study (NCT01677858) is evaluating the safety and efficacy of once-weekly CFZ with dexamethasone (DEX).

Visit our website at: http://www.myeloma.org